Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond

Historically, aspirin has been the primary treatment for the prevention of ischaemic events in patients with coronary artery disease. For patients undergoing percutaneous coronary intervention (PCI) standard treatment has been 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogre...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Rutao, Wu, Sijing, Gamal, Amr, Gao, Chao, Hara, Hironori, Kawashima, Hideyuki, Ono, Masafumi, van Geuns, Robert-Jan, Vranckx, Pascal, Windecker, Stephan, Onuma, Yoshinobu, Serruys, Patrick W, Garg, Scot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566303/
https://www.ncbi.nlm.nih.gov/pubmed/33930107
http://dx.doi.org/10.1093/ehjcvp/pvab035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566303/
https://www.ncbi.nlm.nih.gov/pubmed/33930107
http://dx.doi.org/10.1093/ehjcvp/pvab035

Ejemplares similares